Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Yudai Hinata; Nobumasa Ohara; Yuhki Sakurai; Ryo Koda; Yuichiro Yoneoka; Toshinori Takada; Noboru Hara; Tsutomu Nishiyama

doi:10.12659/AJCR.931639

15 July 2021: Articles

Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Unusual clinical course

Yudai Hinata ^B , Nobumasa Ohara ^A* , Yuhki Sakurai ^C , Ryo Koda ^B , Yuichiro Yoneoka ^C , Toshinori Takada ^C , Noboru Hara ^B , Tsutomu Nishiyama ^B

DOI: 10.12659/AJCR.931639

Am J Case Rep 2021; 22:e931639

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

C: Growth hormone-releasing peptide 2 (GHRP-2) stimulation test performed in November 2019.

	Reference range*	Basal	Peak (time at peak)
Growth hormone (ng/mL)	0–2.47	0.4	45.5 (30 min)
Blood samples were collected in the morning before (basal) and at 15, 30, 45, and 60 min after i.v. administration of 100 μg of GHRP-2. ^* Basal levels.

Back to the Article

Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review

Your Privacy